• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺腺癌中表皮生长因子受体突变状态与 F-氟脱氧葡萄糖正电子发射断层扫描-计算机断层扫描图像特征的相关性。

Correlation between EGFR mutation status and F -fluorodeoxyglucose positron emission tomography-computed tomography image features in lung adenocarcinoma.

机构信息

Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

National Clinical Research Center for Cancer, Tianjin, China.

出版信息

Thorac Cancer. 2019 Apr;10(4):659-664. doi: 10.1111/1759-7714.12981. Epub 2019 Feb 18.

DOI:10.1111/1759-7714.12981
PMID:30776196
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6449228/
Abstract

BACKGROUND

The purpose of this study was to investigate an association between EGFR mutation status and F-fluorodeoxyglucose positron emission tomography-computed tomography ( F-FDG PET-CT) image features in lung adenocarcinoma.

METHODS

Retrospective analysis of the data of 139 patients with lung adenocarcinoma confirmed by surgical pathology who underwent preoperative F-FDG PET-CT was conducted. Correlations between EGFR mutation status, clinical characteristics, and PET-CT parameters, including the maximum standardized uptake value (SUVmax), the mean of the SUV (SUVmean), the peak of the SUV (SUVpeak) of the primary tumor, and the ratio of SUVmax between the primary tumor and the mediastinal blood pool (SUVratio), were statistically analyzed. Multivariate logistic regression analysis was performed to identify predictors of EGFR mutation. Receiver operating characteristic curves of statistical quantitative parameters were compared.

RESULTS

EGFR mutations were detected in 74 (53.2%) of the 139 lung adenocarcinomas and were more frequent in non-smoking patients. Univariate analysis showed that the SUVmax, SUVmean, SUVpeak, and SUVratio were lower in EGFR-mutated than in wild-type tumors. The receiver operating characteristic curves showed no significant differences between their diagnostic efficiencies. Multivariate logistic regression analysis showed that being a never smoker was an independent predictor of EGFR mutation.

CONCLUSION

Quantitative parameters based on F-FDG PET-CT have modest power to predict the presence of EGFR mutation in lung adenocarcinoma; however, when compared to smoking history, they are not good or significant predictive factors.

摘要

背景

本研究旨在探讨肺腺癌中表皮生长因子受体(EGFR)突变状态与 F-氟脱氧葡萄糖正电子发射断层扫描-计算机断层扫描(F-FDG PET-CT)图像特征之间的关系。

方法

对 139 例经手术病理证实为肺腺癌的患者的 F-FDG PET-CT 术前数据进行回顾性分析。对 EGFR 突变状态、临床特征与 PET-CT 参数(包括原发肿瘤的最大标准化摄取值(SUVmax)、SUV 均值(SUVmean)、SUV 峰值(SUVpeak)和原发肿瘤与纵隔血池 SUVmax 比值(SUVratio))之间的相关性进行统计学分析。采用多变量逻辑回归分析识别 EGFR 突变的预测因素。比较统计定量参数的受试者工作特征曲线。

结果

在 139 例肺腺癌中,检测到 74 例(53.2%)EGFR 突变,且在不吸烟者中更为常见。单因素分析显示,EGFR 突变型肿瘤的 SUVmax、SUVmean、SUVpeak 和 SUVratio 均低于野生型肿瘤。受试者工作特征曲线显示,这些定量参数的诊断效能无显著差异。多变量逻辑回归分析显示,从不吸烟是 EGFR 突变的独立预测因素。

结论

F-FDG PET-CT 定量参数对肺腺癌 EGFR 突变的预测能力中等;但与吸烟史相比,其不是良好或显著的预测因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/62f8/6449228/f373278f6c94/TCA-10-659-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/62f8/6449228/f373278f6c94/TCA-10-659-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/62f8/6449228/f373278f6c94/TCA-10-659-g001.jpg

相似文献

1
Correlation between EGFR mutation status and F -fluorodeoxyglucose positron emission tomography-computed tomography image features in lung adenocarcinoma.肺腺癌中表皮生长因子受体突变状态与 F-氟脱氧葡萄糖正电子发射断层扫描-计算机断层扫描图像特征的相关性。
Thorac Cancer. 2019 Apr;10(4):659-664. doi: 10.1111/1759-7714.12981. Epub 2019 Feb 18.
2
[Evaluate the value of (18)F-FDG PET-CT imaging in predicting the mutationsin epidermal growth factor receptor in lung adenocarcinoma].[评估(18)F-FDG PET-CT成像在预测肺腺癌表皮生长因子受体突变中的价值]
Zhonghua Zhong Liu Za Zhi. 2017 Jul 23;39(7):528-531. doi: 10.3760/cma.j.issn.0253-3766.2017.07.010.
3
The value of dynamic FDG PET/CT in the differential diagnosis of lung cancer and predicting EGFR mutations.动态 FDG PET/CT 在肺癌鉴别诊断和预测 EGFR 突变中的价值。
BMC Pulm Med. 2024 May 10;24(1):227. doi: 10.1186/s12890-024-02997-9.
4
Value of ¹⁸F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma.¹⁸F-FDG 摄取的 PET/CT 值和 CEA 水平对预测肺腺癌中表皮生长因子受体突变的价值。
Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1889-97. doi: 10.1007/s00259-014-2802-y. Epub 2014 May 23.
5
Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma.肺腺癌中 18F-FDG 摄取的 PET-CT 扫描与 EGFR 或 KRAS 突变状态的相关性。
PLoS One. 2017 Apr 19;12(4):e0175622. doi: 10.1371/journal.pone.0175622. eCollection 2017.
6
Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma.晚期肺腺癌中 F-18 氟代脱氧葡萄糖正电子发射断层扫描最大标准化摄取值与表皮生长因子受体突变的相关性。
Med Oncol. 2010 Mar;27(1):9-15. doi: 10.1007/s12032-008-9160-1. Epub 2009 Jan 7.
7
[Semiquantitative parameters of F-FDG PET/CT, gene mutation states of epidermal growth factor receptor and anaplastic lymphoma kinase in prognosis evaluation of patients with lung adenocarcinoma].[¹⁸F-FDG PET/CT半定量参数、表皮生长因子受体和间变性淋巴瘤激酶基因突变状态在肺腺癌患者预后评估中的应用]
Beijing Da Xue Xue Bao Yi Xue Ban. 2020 Oct 20;53(2):246-254. doi: 10.19723/j.issn.1671-167X.2021.02.003.
8
Predictive value of multiple metabolic and heterogeneity parameters of F-FDG PET/CT for EGFR mutations in non-small cell lung cancer.18F-FDG PET/CT 多种代谢和异质性参数对非小细胞肺癌 EGFR 突变的预测价值。
Ann Nucl Med. 2022 Apr;36(4):393-400. doi: 10.1007/s12149-022-01718-8. Epub 2022 Jan 27.
9
Prognostic Value of Baseline 18F-FDG PET/CT Functional Parameters in Patients with Advanced Lung Adenocarcinoma Stratified by EGFR Mutation Status.根据表皮生长因子受体(EGFR)突变状态分层的晚期肺腺癌患者基线18F-氟代脱氧葡萄糖正电子发射断层显像/计算机断层扫描(18F-FDG PET/CT)功能参数的预后价值
PLoS One. 2016 Jun 23;11(6):e0158307. doi: 10.1371/journal.pone.0158307. eCollection 2016.
10
Value of F-FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients.F-FDG PET/CT 预测非小细胞肺癌患者 EGFR 突变和 ALK 阳性表达的价值:849 例中国患者的回顾性分析。
Eur J Nucl Med Mol Imaging. 2018 May;45(5):735-750. doi: 10.1007/s00259-017-3885-z. Epub 2017 Nov 21.

引用本文的文献

1
Performance of [F]FDG PET/CT versus FAPI PET/CT for lung cancer assessment: a systematic review and meta-analysis.[F]FDG PET/CT 与 FAPI PET/CT 用于肺癌评估的性能比较:系统评价和荟萃分析。
Eur Radiol. 2024 Feb;34(2):1077-1085. doi: 10.1007/s00330-023-10013-7. Epub 2023 Aug 17.
2
Prediction of the Presence of Targetable Molecular Alteration(s) with Clinico-Metabolic F-FDG PET Radiomics in Non-Asian Lung Adenocarcinoma Patients.利用临床代谢型¹⁸F-FDG PET影像组学预测非亚洲肺腺癌患者中可靶向分子改变的存在情况
Diagnostics (Basel). 2022 Oct 10;12(10):2448. doi: 10.3390/diagnostics12102448.
3
Recent and current advances in PET/CT imaging in the field of predicting epidermal growth factor receptor mutations in non-small cell lung cancer.

本文引用的文献

1
EGFR mutation decreases FDG uptake in non‑small cell lung cancer via the NOX4/ROS/GLUT1 axis.表皮生长因子受体(EGFR)突变通过NADPH氧化酶4(NOX4)/活性氧(ROS)/葡萄糖转运蛋白1(GLUT1)轴降低非小细胞肺癌中的氟代脱氧葡萄糖(FDG)摄取。
Int J Oncol. 2019 Jan;54(1):370-380. doi: 10.3892/ijo.2018.4626. Epub 2018 Nov 6.
2
Overview of current systemic management of EGFR-mutant NSCLC.表皮生长因子受体突变型非小细胞肺癌的现行全身治疗概述。
Ann Oncol. 2018 Jan 1;29(suppl_1):i3-i9. doi: 10.1093/annonc/mdx702.
3
Value of F-FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients.
PET/CT成像在预测非小细胞肺癌表皮生长因子受体突变领域的最新及当前进展。
Front Oncol. 2022 Oct 6;12:879341. doi: 10.3389/fonc.2022.879341. eCollection 2022.
4
Comparison of Ga-FAPI and F-FDG PET/CT in the Evaluation of Patients With Newly Diagnosed Non-Small Cell Lung Cancer.镓标记的纤维连接蛋白激活肽成像(Ga-FAPI)与氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(F-FDG PET/CT)在初诊非小细胞肺癌患者评估中的比较
Front Oncol. 2022 Jul 4;12:924223. doi: 10.3389/fonc.2022.924223. eCollection 2022.
5
Relationship between F-FDG PET/CT Semi-Quantitative Parameters and International Association for the Study of Lung Cancer, American Thoracic Society/European Respiratory Society Classification in Lung Adenocarcinomas.肺腺癌中 F-FDG PET/CT 半定量参数与国际肺癌研究协会、美国胸科学会/欧洲呼吸学会分类的关系。
Korean J Radiol. 2022 Jan;23(1):112-123. doi: 10.3348/kjr.2021.0455.
6
Can F-FDG PET/CT predict EGFR status in patients with non-small cell lung cancer? A systematic review and meta-analysis.18F-氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描能否预测非小细胞肺癌患者的表皮生长因子受体状态?系统评价和荟萃分析。
BMJ Open. 2021 Jun 8;11(6):e044313. doi: 10.1136/bmjopen-2020-044313.
7
Biological Significance of F-FDG PET/CT Maximum Standard Uptake Value for Predicting Mutation Status in Non-Small Cell Lung Cancer Patients.¹⁸F-FDG PET/CT最大标准摄取值对预测非小细胞肺癌患者突变状态的生物学意义
Int J Gen Med. 2021 Feb 3;14:347-356. doi: 10.2147/IJGM.S287506. eCollection 2021.
8
Diagnostic and Predictive Values of F-FDG PET/CT Metabolic Parameters in -Mutated Advanced Lung Adenocarcinoma.F-FDG PET/CT代谢参数在KRAS突变型晚期肺腺癌中的诊断及预测价值
Cancer Manag Res. 2020 Jul 28;12:6453-6465. doi: 10.2147/CMAR.S259055. eCollection 2020.
9
Value of combining PET/CT and clinicopathological features in predicting EGFR mutation in Lung Adenocarcinoma with Bone Metastasis.PET/CT与临床病理特征相结合在预测肺腺癌骨转移患者表皮生长因子受体(EGFR)突变中的价值
J Cancer. 2020 Jul 11;11(18):5511-5517. doi: 10.7150/jca.46414. eCollection 2020.
10
Predicting EGFR mutation subtypes in lung adenocarcinoma using F-FDG PET/CT radiomic features.利用F-FDG PET/CT影像组学特征预测肺腺癌中的表皮生长因子受体(EGFR)突变亚型
Transl Lung Cancer Res. 2020 Jun;9(3):549-562. doi: 10.21037/tlcr.2020.04.17.
F-FDG PET/CT 预测非小细胞肺癌患者 EGFR 突变和 ALK 阳性表达的价值:849 例中国患者的回顾性分析。
Eur J Nucl Med Mol Imaging. 2018 May;45(5):735-750. doi: 10.1007/s00259-017-3885-z. Epub 2017 Nov 21.
4
EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).非小细胞肺癌中腺癌组织学的 EGFR 突变发生率:按种族的系统评价和全球图谱(mutMapII)。
Am J Cancer Res. 2015 Aug 15;5(9):2892-911. eCollection 2015.
5
FDG uptake in non-small cell lung cancer is not an independent predictor of EGFR or KRAS mutation status: a retrospective analysis of 206 patients.非小细胞肺癌中 FDG 摄取与 EGFR 或 KRAS 基因突变状态无关:206 例患者的回顾性分析。
Clin Nucl Med. 2015 Dec;40(12):950-8. doi: 10.1097/RLU.0000000000000975.
6
Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.[¹⁸F]氟代脱氧葡萄糖正电子发射断层扫描在预测晚期非小细胞肺癌患者KRAS和表皮生长因子受体突变状态中的作用
Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2058-65. doi: 10.1007/s00259-014-2833-4. Epub 2014 Jul 3.
7
Epidermal growth factor receptor (EGFR) signaling regulates global metabolic pathways in EGFR-mutated lung adenocarcinoma.表皮生长因子受体(EGFR)信号通路调节 EGFR 突变型肺腺癌中的全局代谢途径。
J Biol Chem. 2014 Jul 25;289(30):20813-23. doi: 10.1074/jbc.M114.575464.
8
Value of ¹⁸F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma.¹⁸F-FDG 摄取的 PET/CT 值和 CEA 水平对预测肺腺癌中表皮生长因子受体突变的价值。
Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1889-97. doi: 10.1007/s00259-014-2802-y. Epub 2014 May 23.
9
Correlation of Glut-1 glucose transporter expression with [(18)F]FDG uptake in non-small cell lung cancer.非小细胞肺癌中葡萄糖转运蛋白1(Glut-1)表达与[18F]氟代脱氧葡萄糖(FDG)摄取的相关性
Eur J Nucl Med. 2000 Dec;27(12):1778-85. doi: 10.1007/s002590000367.
10
Cancer statistics, 2014.癌症统计数据,2014 年。
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29. doi: 10.3322/caac.21208. Epub 2014 Jan 7.